Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04216316
Title Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatments (Carboplatin and Gemcitabine) and to Avelumab for Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

lung non-small cell carcinoma


Avelumab + Carboplatin + Gemcitabine

Avelumab + Berzosertib + Carboplatin + Gemcitabine

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.